Related Experiment Video
Updated: Jun 20, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic therapy for heart failure in sinus rhythm
Veeran Subramaniam1, Russell C Davis, Eduard Shantsila
1Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Fundamental & Clinical Pharmacology
|September 9, 2009
Summary
For patients with chronic heart failure, the benefits of anticoagulation versus antiplatelet therapy for preventing thromboembolism are unclear. Early studies suggest anticoagulation may reduce heart failure hospitalizations.
Area of Science:
- Cardiology
- Thrombosis Research
- Heart Failure Management
Background:
- Chronic heart failure (CHF) patients face a high risk of thromboembolism, even without atrial fibrillation.
- Current evidence on antithrombotic therapy (anticoagulation vs. antiplatelet) in this population is limited and poorly defined.
- Previous analyses of heart failure trials suggest thromboembolism risks ranging from 1% to 4.5%.
Purpose of the Study:
- To evaluate the risk-benefit ratio of anticoagulation versus antiplatelet therapy or no antithrombotic treatment in chronic heart failure patients.
- To clarify the optimal antithrombotic strategy for reducing thromboembolic events in this patient group.
Main Methods:
- Review of post hoc analyses from large therapeutic heart failure trials.
- Analysis of available randomized studies on anticoagulation and antiplatelet therapy in CHF.
- Awaiting results from ongoing large-scale randomized controlled trials.
Main Results:
- Thromboembolism risk in CHF without atrial fibrillation is estimated between 1% and 4.5% in some analyses.
- Existing randomized studies show a trend favoring anticoagulation therapy.
- Anticoagulation therapy may lead to fewer heart failure hospitalizations compared to aspirin use.
Conclusions:
- The optimal antithrombotic strategy for chronic heart failure patients without atrial fibrillation remains uncertain.
- Further large-scale randomized trials are necessary to establish definitive evidence.
- A potential benefit of anticoagulation in reducing heart failure hospitalizations warrants further investigation.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...